Effects of interventions for the treatment of nocturnal enuresis in children

C M A Glazener, R E Peto, J H C Evans

The effectiveness of interventions for the treatment of nocturnal enuresis in children published in a recent issue of *Effective Health Care* is reviewed.

This article is based on a recent issue of *Effective Health Care* which focused on the effects of interventions for the treatment of non-organic nocturnal enuresis in children. Nocturnal enuresis (bedwetting) is the involuntary loss of urine at night, in the absence of physical disease, at an age when a child could reasonably be expected to be dry (by consensus, at a developmental age of 5 years). Although bedwetting has a high rate of spontaneous remission, it may bring social and emotional stigma, stress and inconvenience to both the person with enuresis and their families. Children who wet the bed may experience parental disapproval, sibling teasing, and repeated treatment failure which may lower self-esteem. Nocturnal enuresis affects many families. Estimating the prevalence of nocturnal enuresis is difficult, however, because there is variation in methods of diagnosis and in definitions. In the UK, the most recent estimates suggest that the prevalence of frequent bedwetting (more than once a week) is higher in boys and shows a steady decline with age. Around one in six children aged 5 years regularly wet the bed compared with around one in 20 children aged 11 years.

Various interventions are used to treat nocturnal enuresis (Box 1). These include enuresis alarms, drugs such as desmopressin, simple behavioural methods such as star charts, and more complex behavioural methods including dry bed training. Other less common interventions include psychotherapy, surgery, fluid deprivation, and complementary therapies.

**Box 1 Interventions used to treat nocturnal enuresis**

**Behavioural interventions**
- **Lifting**: involving taking the child to the toilet during the night usually before the time that bedwetting is expected, without necessarily waking the child.
- **Waking**: involves waking the child to allow him/her to get up and urinate.
- **Reward systems** (e.g. star charts): the child might receive a star for every dry night, and a reward after a preset number of stars have been earned.
- **Retention control training**: attempting to increase the functional bladder capacity by delaying urination for extended periods of time during the day.
- **Stop-start training**: teaching children to interrupt their stream of urine in order to strengthen their pelvic floor muscles.
- **Dry bed training** can include enuresis alarms, waking routines, positive practice, cleanliness training, bladder training, and rewards.

**Enuresis alarms**
- Enuresis alarms wake the child in the night at the onset of wetting. When a child begins to urinate a sensor (either a bed pad or one worn inside pyjamas) is moistened and the alarm is triggered.
- **Overlearning**: may be initiated after successful alarm treatment (e.g. achievement of 14 consecutive dry nights). Extra drinks are given at bedtime to cause additional stress to the detrusor muscles in the bladder. Alarm treatment is then continued until 14 consecutive dry nights are once again achieved.

**Pharmacological interventions**
- Drugs used include desmopressin and, less commonly, tricyclic drugs such as imipramine, amitriptyline, and norriptiline.
and potential bias. In addition, many are poorly reported. For example, many trial authors give insufficient detail about the method of randomisation or adequately report follow up data. A number of the included RCTs have recruited children by advertising in the media or from enuresis clinics. Participating families may have been especially motivated to tackle the bed wetting. In addition, strict inclusion/exclusion criteria were imposed in many of the trials. Consequently, the children involved are not necessarily representative of the wider population of those who wet the bed, either in the community or in institutions.

EFFECTIVENESS

Behavioural interventions other than alarms

Simple behavioural interventions are widely used as standard first line treatment. Twelve RCTs were included in a Cochrane review assessing the effects of simple behavioural interventions.31 None were of good methodological quality. The review found that star charts, with or without lifting or waking, were associated with significantly fewer wet nights and lower failure rates while on treatment and higher long term success after treatment. However, each finding was based on a single small trial. Of the two trials addressing retention control training, one was too small to provide meaningful information and the other had a very high dropout rate (80%). Another small trial showed that there might be some benefits associated with cognitive therapy compared with star charts, but these findings will need to be confirmed in other larger trials.

A feature of the included RCTs was high dropout or non-adherence rates. Families reported that waking the child at night was disruptive and often too stressful, raising the possibility that some of these simple behavioural interventions may not be suitable for all.

A number of RCTs have been conducted to assess the effectiveness of complex behavioural treatment programmes such as dry bed training. Although originally reviewed in the 1997 systematic review undertaken by CRD,12 an update is nearing completion and will be available as a Cochrane review later this year.13

Alarms

Fifty three RCTs were included in a Cochrane review assessing the effects of alarm interventions for nocturnal enuresis.13 The methodological quality of many of the RCTs was poor. Many were too small to be likely to find statistically significant differences, even where some difference may exist, and often only one small trial compared alarms with another method. In these circumstances no conclusions can be drawn.

The main findings of the review were that alarm treatment was more effective during treatment than control interventions (fig 1) and in terms of success rates after treatment was completed (fig 2). About half the children remained dry after using alarms compared with almost none of those who received no treatment or waiting list control (RR 12.67, 95% CI 4.06 to 39.52).

Most of the alarms evaluated were of the type that woke the child immediately by means of a bell or buzzer. Insufficient evidence was found to draw conclusions about the relative effectiveness of different types of alarm, although some types may be more effective. There was some limited evidence that an immediate alarm was better than a delayed alarm, and that one which woke the child rather than the parents had better results. Children were reported to prefer a body-worn alarm to a bed pad and alarm.

The Cochrane review included eight RCTs which compared alarms with a variety of simple behavioural interventions including star charts, rewards, waking, lifting and stop-start training (pelvic floor muscle training).13 Most of the trials comparing behavioural interventions with alarms tended to favour alarable forms. Alarms were found to be better than stop-start training in terms of wet nights per week, both during and after treatment, in one small trial. There were no statistically
significant differences between alarms and methods such as lifting, waking, or rewards in four other small trials, although all trials favoured alarms in respect of a reduction in mean wet nights. There was not enough evidence to conclude whether supplementing alarm treatment with behavioural interventions improved the effectiveness of the alarm.

The Cochrane review included 18 RCTs that involved comparisons between alarms and drugs, either alone or in combination. Limited evidence suggested that alarms were better than drug treatment. Although desmopressin appeared to have a more immediate effect, alarms were more effective by the end of a course of treatment (RR 0.71, 95% CI 0.50 to 0.99) and after treatment stopped (RR 0.27, 95% CI 0.11 to 0.69). Alarms were also found to be better than tricyclic antidepressants both during (RR 0.73, 95% CI 0.61 to 0.88) and after treatment stopped (RR 0.58, 95% CI 0.36 to 0.94).

Insufficient reliable evidence was found supporting the practice of supplementing alarm treatment with drug interventions.

Most alarms wake the child immediately using a bell or buzzer but then require nighttime, and perhaps bed-wetting, to be changed. High dropout rates in some of the trials included in the Cochrane review suggest that there were problems with adherence, often reflecting the unacceptability of the intervention. Potential difficulties such as the time needed to attain success and the disruption to the family need to be discussed before embarking on alarm treatment. In two trials non-adherence or dropout was attributed to the equipment being too difficult or complicated to use. A small number of RCTs included in the review involved alarms which delivered electric shocks to the children’s skin. The use of these alarms was clearly unacceptable to parents and children, and they sometimes caused side effects such as skin burns and ulceration.

**Drugs**

Three Cochrane reviews have assessed the effects of drug therapy on nocturnal enuresis in children. One of these reviews covers the less commonly used drugs and is currently being updated and will be available later this year.

Forty one RCTs were included in a Cochrane review assessing the effects of desmopressin. The review found that there was clear evidence that desmopressin (in a variety of doses and forms) was better at reducing the number of wet nights per week during treatment than placebo (fig 3). However, after treatment stopped the limited evidence available suggested that this improvement was not sustained.

Another Cochrane review of 54 RCTs found that treatment with tricyclic or related drugs (imipramine, amitriptyline, viloxazine, clomipramine and desipramine but not mianserin) was associated with a reduction of about one wet night per week while on treatment. For example, imipramine was better at reducing the number of wet nights per week during treatment than placebo (weighted mean difference –1.19, 95% CI –1.56 to –0.82). However, although about a fifth of the children became dry while on treatment (86/400 achieved 14 dry nights on imipramine compared with 22/413 on placebo), this effect was not sustained after treatment stopped (6/192 on imipramine compared with 7/209 on placebo).

Insufficient reliable evidence was found comparing desmopressin with tricyclics or other related drugs. Likewise, there was a lack of reliable evidence comparing desmopressin or tricyclics with simple and complex behavioural interventions.

The British National Formulary (BNF) currently suggests that drug therapy is not usually appropriate for children under 7 years of age and should be reserved for children in whom alternative measures have failed. Fluid overload is potentially the most serious complication with desmopressin. It is associated with overdrinking at bedtime and its symptoms include headache, nausea, hyponatraemia, cerebral oedema, and convulsions. Tricyclic antidepressants have significant adverse effects including cardiotoxic and hepatotoxic effects in overdose. Minor side effects related to their anticholinergic actions include postural hypotension, dry mouth, constipation, perspiration, tachycardia, nausea, lethargy and insomnia. The BNF recommends that the possible side effects of the various drugs should be considered and that any prescription should not be continued for longer than 3 months without stopping for a full reassessment.

**IMPLICATIONS**

Much of the available research on the effects of interventions used to treat nocturnal enuresis in children is of poor quality and there are few direct comparisons between different types of intervention.

Simple behavioural interventions are widely used as standard first line treatment but they can require a high level of parental involvement. There is currently little evidence to show that these interventions work.

The use of an alarm intervention has been shown to reduce night time bed wetting in most children both during treatment and after treatment stops. Overlearning (giving children extra fluids at bedtime after successfully becoming dry using an alarm) may reduce the relapse rate. Before embarking on alarm treatment, families need to be made

---

**Figure 2**  Comparison of alarm treatment with control interventions on the number of children with nocturnal enuresis who achieved 14 consecutive dry nights and did not relapse.
Effects of interventions for the treatment of nocturnal enuresis in children

### Table: Comparison of Desmopressin vs Placebo

<table>
<thead>
<tr>
<th>Study or sub-category</th>
<th>Desmopressin Mean (SD) N</th>
<th>Placebo Mean (SD) N</th>
<th>WMD (95% CI)</th>
<th>Weight (%)</th>
<th>WMD (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>10 µg vs placebo</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Aalders (1982)</td>
<td>1.52 (2.15) 15</td>
<td>1.44 (1.94) 17</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Koller (1984)</td>
<td>2.49 (2.32) 12</td>
<td>3.84 (2.13) 12</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Subtotal (95% CI)</strong></td>
<td>28</td>
<td>29</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Test for heterogeneity:</strong></td>
<td>$\chi^2 = 1.68$, df = 1 ($p = 0.20$), $I^2 = 40.4%$</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Test for overall effect:</strong></td>
<td>$Z = 4.01$ ($p &lt; 0.001$)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

| **20 µg vs placebo**  |                          |                     |              |            |              |
| Forre (1997) #        | 3.34 (2.51) 31           | 4.86 (1.95) 31      |              |            |              |
| Torrens (1992) #      | 1.60 (1.30) 18           | 3.97 (2.20) 18      |              |            |              |
| Segre (1985)          | 2.20 (1.36) 20           | 4.02 (1.79) 20      |              |            |              |
| Post (1983) A #       | 4.90 (1.92) 20           | 5.80 (1.14) 20      |              |            |              |
| Koller (1984)         | 2.45 (1.84) 12           | 3.84 (2.13) 12      |              |            |              |
| Tuch (1984) #         | 5.16 (2.00) 54           | 4.02 (1.85) 54      |              |            |              |
| Janknegt (1990) #     | 3.40 (2.50) 22           | 5.30 (1.80) 22      |              |            |              |
| Rushion (1995)        | 4.39 (2.37) 47           | 4.90 (1.64) 47      |              |            |              |
| Skog (1997) #         | 4.00 (1.15) 36           | 5.00 (1.20) 36      |              |            |              |
| Seer (1998)           | 3.10 (1.39) 25           | 5.10 (2.00) 25      |              |            |              |
| Schrân (2001a)        | 4.00 (1.33) 47           | 4.50 (1.37) 47      |              |            |              |
| Schrân (2001b)        | 4.00 (1.57) 38           | 5.00 (1.54) 38      |              |            |              |
| **Subtotal (95% CI)** | 211                      | 213                 |              |            |              |
| **Test for heterogeneity:** | $\chi^2 = 3.11$, df = 5 ($p = 0.68$), $I^2 = 0\%$ | | | | |
| **Test for overall effect:** | $Z = 7.62$ ($p < 0.0001$) | | | | |

| **60 µg vs placebo**  |                          |                     |              |            |              |
| Skog (1997) #         | 3.50 (1.15) 36           | 5.00 (1.20) 36      |              |            |              |
| Schrân (2001a)        | 3.00 (1.73) 47           | 4.50 (1.37) 47      |              |            |              |
| **Subtotal (95% CI)** | 81                       | 83                  |              |            |              |
| **Test for heterogeneity:** | $\chi^2 = 0.00$, df = 1 ($p = 1.00$), $I^2 = 0\%$ | | | | |
| **Test for overall effect:** | $Z = 7.08$ ($p < 0.0001$) | | | | |

| **Combined dose vs placebo** |                          |                     |              |            |              |
| Briersen (1976) #      | 2.10 (2.25) 22           | 5.50 (2.20) 22      |              |            |              |
| **Subtotal (95% CI)**  | 100.00                   | 0.00                |              |            |              |
| **Test for heterogeneity:** | $\chi^2 = 3.40$, df = 1 ($p = 0.04$) | | | | |
| **Test for overall effect:** | $Z = 7.62$ ($p < 0.0001$) | | | | |

**Figure 3** Comparison of desmopressin versus placebo on number of wet nights per week during treatment in children with nocturnal enuresis.

aware of both the time and the high level of parental involvement necessary to attain success.

Drug treatment such as desmopressin reduces the number of wet nights per week compared with placebo, but only for as long as the drug is used. However, drugs can be used as a way to reduce the frequency of wetting for a specific purpose such as nights away from home—for example, for holidays or when staying with friends. Patients and their families need to be warned about possible side effects of some of the drugs.

Future research must be of higher methodological quality, involve comparisons between those interventions used most commonly in practice, be undertaken in appropriate settings, and include follow up periods of longer duration.

**Authors’ affiliations**

C M A Glazener, Health Services Research Unit, University of Aberdeen, UK

R E Peto, Centre for Reviews and Dissemination, University of York, UK

J H C Evans, Nottingham City Hospital NHS Trust, Nottingham, UK

**REFERENCES**


Effects of interventions for the treatment of nocturnal enuresis in children

C M A Glazener, R E Peto and J H C Evans

Qual Saf Health Care 2003 12: 390-394
doi: 10.1136/qhc.12.5.390

Updated information and services can be found at:
http://qualitysafety.bmj.com/content/12/5/390

These include:

References
This article cites 1 articles, 0 of which you can access for free at:
http://qualitysafety.bmj.com/content/12/5/390#BIBL

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/